NASDAQ:ATRC - AtriCure Stock Price, Forecast & News

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

AtriCure Inc. (NASDAQ:ATRC) posted its quarterly earnings data on Wednesday, October, 30th. The medical device company reported ($0.25) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.28) by $0.03. The medical device company had revenue of $56.60 million for the quarter, compared to analysts' expectations of $55.12 million. AtriCure had a negative net margin of 10.13% and a negative return on equity of 13.59%. The business's quarterly revenue was up 13.4% on a year-over-year basis. During the same quarter last year, the company posted ($0.24) EPS. View AtriCure's Earnings History.

AtriCure is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for AtriCure.

AtriCure issued an update on its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $61.3-61.3 million, compared to the consensus revenue estimate of $59.24 million.

5 brokerages have issued 12-month price targets for AtriCure's shares. Their forecasts range from $30.00 to $48.00. On average, they anticipate AtriCure's stock price to reach $39.40 in the next twelve months. This suggests a possible upside of 4.9% from the stock's current price. View Analyst Price Targets for AtriCure.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AtriCure.

Headlines about ATRC stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AtriCure earned a news impact score of -1.4 on InfoTrie's scale. They also assigned news stories about the medical device company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for AtriCure.

Some companies that are related to AtriCure include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Steris (STE).

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Amgen (AMGN), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Enterprise Products Partners (EPD), Cellectis (CLLS), Abbott Laboratories (ABT), Alnylam Pharmaceuticals (ALNY), bluebird bio (BLUE) and DexCom (DXCM).

AtriCure's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (1.93%). Company insiders that own AtriCure stock include Douglas J Seith, Elizabeth D Krell, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel and Regina E Groves. View Institutional Ownership Trends for AtriCure.

ATRC stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold AtriCure company stock in the last year include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar and Michael H Carrel. View Insider Buying and Selling for AtriCure.

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ATRC stock can currently be purchased for approximately $37.57.

AtriCure has a market capitalization of $1.49 billion and generates $201.63 million in revenue each year. The medical device company earns $-21,140,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. AtriCure employs 620 workers across the globe.View Additional Information About AtriCure.

The official website for AtriCure is http://www.atricure.com/.

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.